Home / Catalogue/ Healing repair/ Ara-290

Healing repairIn StockSubQ injection

Ara-290

Peptide · EPO helix B surface peptide · Synthetic

Half-life

~2-3min

After administration

Delivery Method

SubQ injection

Route of administration

Storage (Lyophilised)

12-24 months

2–8°C

Storage (Reconstituted)

3–4 weeks

Refrigerate at 2-8C

Known For

Non-erythropoietic EPO derivative. Activates the innate repair receptor (IRR) without stimulating red blood cell production. Neuroprotective and tissue-protective. Being studied for neuropathic pain and small fiber neuropathy.

Mechanism of Action

Erythropoietin-derived peptide — activates innate repair receptor (IRR) WITHOUT stimulating red blood cell production. Neuroprotective, tissue-protective, anti-inflammatory.

Body vs. External Supply

🔴 Exogenous (replaces natural)

Brand / Trade Names

Cibinetide (INN name) Developer: Araim Pharmaceuticals Phase 2 completed Not yet approved

Typical Research Dosage

2-4mg SubQ daily or 3x per week. Clinical trials used 2mg IV.

Vial Duration Guide

10mg vial at 2mg/day = 5 days.

Recommended Vial Size

★ 10mg (only size) At 2mg/day = 5 days ✓. At 4mg/day = 2.5 days ✓. No shelf life issues.

Time to Effects

EARLY: 1-2 weeks FULL: 4-8 weeks Week 1-2: Neuropathic pain reduction beginning. Tissue-protective effects initiating. Week 2-4: Significant pain improvement in responsive patients. Nerve function improving. Week 4-8: Maximum benefit for neuropathic conditions. Small fiber neuropathy improvement measurable. Most noticeable in patients with neuropathic pain or small fiber neuropathy. Minimum commitment: 4 weeks.

Contraindications & Do Not Combine

No strict contraindications with other peptides on this list. ⚠️ WADA PROHIBITED — S2 category (non-erythropoietic EPO receptor agonists). Do not use in competitive sport.

Common Side Effects

Generally well tolerated in trials. Injection site reaction, headache (mild), dizziness. No EPO-like side effects (no polycythaemia/thrombosis).

Drug Interactions

EPO (theoretical interaction at high doses — but Ara-290 doesn't activate classical EPO pathway). Minimal known interactions.

Reversibility

Reversible — neuroprotective/repair effects may persist beyond treatment period

Key Peer-Reviewed References

All studies are published in indexed journals unless otherwise noted.

• Brines et al. (2008) PNAS 105:10925-30 — Non-erythropoietic EPO derivative • Brines et al. (2014) Mol Med 20:559-68 — Neuropathic pain pilot • Araim Pharmaceuticals development • NOT FDA APPROVED • Phase 2 data for sarcoidosis and diabetic neuropathy • Unique mechanism: innate repair receptor activation without blood cell production

Research Disclaimer

Almost all data is preclinical (animal or in-vitro). No large-scale randomised controlled human trials are available for most compounds on this catalogue. This information is provided for research reference only.

Storage Requirements

2-8°C. Research supply.

State	Condition	Duration
Lyophilised (sealed)	2–8°C	12-24 months
Reconstituted	2-8C	3–4 weeks

Reconstitution Note

Reconstitute with bacteriostatic water (BAC water). Do not shake vigorously -- swirl gently to dissolve. Inject BAC water slowly down the side of the vial to avoid denaturing the peptide.

Video Resources

Ara-290 discussed by researchers & practitioners

Independent educational content from researchers, clinicians, and science communicators. Not affiliated with Pepnerd — provided as supplementary reading.

Educational resources only. The videos above are independent third-party content from researchers, clinicians, and science communicators. Pepnerd is not affiliated with any of these creators and does not endorse or make any claims based on their content. All products are sold strictly for in-vitro scientific research.

Select Vial Size

$75.00 per vial

Submit Your Test Results →

Quick Reference

Half-life	~2-3 minutes (IV) \| ~10-30 minutes (SubQ)
Delivery	SubQ injection
Typical dose	2-4mg
Storage (lyoph.)	2–8°C
Storage (recon.)	3–4 weeks
Endogenous?	Exogenous (replaces natural)
Suppression	None known
WADA	Not listed — investigational
FDA status	Phase 2 trials